209 related articles for article (PubMed ID: 9680339)
1. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
Richardson PG; Elias AD; Krishnan A; Wheeler C; Nath R; Hoppensteadt D; Kinchla NM; Neuberg D; Waller EK; Antin JH; Soiffer R; Vredenburgh J; Lill M; Woolfrey AE; Bearman SI; Iacobelli M; Fareed J; Guinan EC
Blood; 1998 Aug; 92(3):737-44. PubMed ID: 9680339
[TBL] [Abstract][Full Text] [Related]
2. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
Richardson PG; Murakami C; Jin Z; Warren D; Momtaz P; Hoppensteadt D; Elias AD; Antin JH; Soiffer R; Spitzer T; Avigan D; Bearman SI; Martin PL; Kurtzberg J; Vredenburgh J; Chen AR; Arai S; Vogelsang G; McDonald GB; Guinan EC
Blood; 2002 Dec; 100(13):4337-43. PubMed ID: 12393437
[TBL] [Abstract][Full Text] [Related]
3. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.
Chopra R; Eaton JD; Grassi A; Potter M; Shaw B; Salat C; Neumeister P; Finazzi G; Iacobelli M; Bowyer K; Prentice HG; Barbui T
Br J Haematol; 2000 Dec; 111(4):1122-9. PubMed ID: 11167751
[TBL] [Abstract][Full Text] [Related]
4. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
[TBL] [Abstract][Full Text] [Related]
5. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
Richardson PG; Soiffer RJ; Antin JH; Uno H; Jin Z; Kurtzberg J; Martin PL; Steinbach G; Murray KF; Vogelsang GB; Chen AR; Krishnan A; Kernan NA; Avigan DE; Spitzer TR; Shulman HM; Di Salvo DN; Revta C; Warren D; Momtaz P; Bradwin G; Wei LJ; Iacobelli M; McDonald GB; Guinan EC
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1005-17. PubMed ID: 20167278
[TBL] [Abstract][Full Text] [Related]
6. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
[TBL] [Abstract][Full Text] [Related]
7. Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation.
Myers KC; Dandoy C; El-Bietar J; Davies SM; Jodele S
Biol Blood Marrow Transplant; 2015 Feb; 21(2):379-81. PubMed ID: 25300869
[TBL] [Abstract][Full Text] [Related]
8. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation.
Richardson PG; Smith AR; Kernan NA; Lehmann L; Soiffer RJ; Ryan RJ; Tappe W; Grupp S
Br J Haematol; 2020 Aug; 190(4):583-587. PubMed ID: 32157682
[TBL] [Abstract][Full Text] [Related]
10. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.
Corbacioglu S; Carreras E; Mohty M; Pagliuca A; Boelens JJ; Damaj G; Iacobelli M; Niederwieser D; Olavarría E; Suarez F; Ruutu T; Verdonck L; Hume R; Nejadnik B; Lai C; Finetto G; Richardson P
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1874-1882. PubMed ID: 27397724
[TBL] [Abstract][Full Text] [Related]
11. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
[TBL] [Abstract][Full Text] [Related]
12. Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.
Triplett BM; Kuttab HI; Kang G; Leung W
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2148-2153. PubMed ID: 26278046
[TBL] [Abstract][Full Text] [Related]
13. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
14. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
[TBL] [Abstract][Full Text] [Related]
15. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
Ho VT; Revta C; Richardson PG
Bone Marrow Transplant; 2008 Feb; 41(3):229-37. PubMed ID: 17994121
[TBL] [Abstract][Full Text] [Related]
16. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
17. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
[TBL] [Abstract][Full Text] [Related]
19. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
Haussmann U; Fischer J; Eber S; Scherer F; Seger R; Gungor T
Haematologica; 2006 Jun; 91(6):795-800. PubMed ID: 16769582
[TBL] [Abstract][Full Text] [Related]
20. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention.
Corbacioglu S; Greil J; Peters C; Wulffraat N; Laws HJ; Dilloo D; Straham B; Gross-Wieltsch U; Sykora KW; Ridolfi-Lüthy A; Basu O; Gruhn B; Güngör T; Mihatsch W; Schulz AS
Bone Marrow Transplant; 2004 Jan; 33(2):189-95. PubMed ID: 14661036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
